ORIC PHARMAC.INC.DL-0001
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor… Read more
Market Cap & Net Worth: ORIC PHARMAC.INC.DL-0001 (4TZ)
ORIC PHARMAC.INC.DL-0001 (F:4TZ) has a market capitalization of $999.67 Million (€973.89 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #9037 globally and #975 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ORIC PHARMAC.INC.DL-0001's stock price €10.00 by its total outstanding shares 97389279 (97.39 Million).
ORIC PHARMAC.INC.DL-0001 Market Cap History: 2020 to 2026
ORIC PHARMAC.INC.DL-0001's market capitalization history from 2020 to 2026. Data shows change from $3.16 Billion to $999.67 Million (-13.96% CAGR).
ORIC PHARMAC.INC.DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ORIC PHARMAC.INC.DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4TZ by Market Capitalization
Companies near ORIC PHARMAC.INC.DL-0001 in the global market cap rankings as of March 19, 2026.
Key companies related to ORIC PHARMAC.INC.DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ORIC PHARMAC.INC.DL-0001 Historical Marketcap From 2020 to 2026
Between 2020 and today, ORIC PHARMAC.INC.DL-0001's market cap moved from $3.16 Billion to $ 999.67 Million, with a yearly change of -13.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €999.67 Million | +44.93% |
| 2025 | €689.78 Million | -11.54% |
| 2024 | €779.75 Million | -4.88% |
| 2023 | €819.73 Million | +62.38% |
| 2022 | €504.84 Million | -62.03% |
| 2021 | €1.33 Billion | -57.91% |
| 2020 | €3.16 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of ORIC PHARMAC.INC.DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $999.67 Million USD |
| MoneyControl | $999.67 Million USD |
| MarketWatch | $999.67 Million USD |
| marketcap.company | $999.67 Million USD |
| Reuters | $999.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.